Navigation Links
Experimental SARS Vaccine

Latest research reveals a SARS vaccine may be on the horizon. Researchers from the National Institutes of Health report promising results from a study involving eight African green monkeys. Four of the monkeys were // immunized against the SARS virus using an intranasal vaccine made from a parainfluenza vaccine originally developed for children. The vaccine was reengineered to express a major antigen of the coronavirus that causes SARS. The other four monkeys did not receive the vaccine. About a month later, all were deliberately infected with SARS.

Results showed the monkeys who received the vaccine had developed antibodies to the SARS virus in their blood, indicating the vaccine was working. They also had no evidence of the virus in their respiratory tract. The monkeys that were not vaccinated, however, showed evidence of active infection within five to eight days of receiving the virus.

In another study, investigators tested another type of SARS prevention, known as a neutralizing human monoclonal antibody, in ferrets that were also deliberately infected with SARS. Results showed the animals had significantly reduced levels of the virus in their lungs and did not develop any SARS-induced lung damage.

Researchers say, though further studies are required before these concepts can be applied to human beings, the findings provide exciting strategies for the prevention of disease in target communities and treatment of at-risk individuals.
'"/>




Page: 1

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. Experimental drug to fight flu
3. Experimental vaccine for shingles is effective
4. Experimental Blood Test May Spot Heart Attack Risk, Study Says
5. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
6. Protection against HIV and Herpes is possible with the Experimental Microbicide
7. Experimental Therapy Effective Against Malignant Melanoma in Horses
8. Experimental Alzheimer’s Drug curbs the disease in mic
9. New Guidelines to Be Laid While Testing Experimental Drugs
10. Experimental Drug Deals Effectively with Prostate Cancer Cells
11. Experimental Drug Causes Cytokine Storm
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, ... with the Fertility Center of California, is pleased to announce the addition of ... and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used ...
(Date:6/26/2017)... ... 26, 2017 , ... If the devil is in the ... these days. According to recent estimates, 75 – 80% of the medical bills ... studies point to Electronic Health Records (EHR) with automated features designed to ease ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United States Senate on Thursday ... Better Care Reconciliation Act. It differs significantly from the American Health Care Act, which ... in committee, or the House will have to take up the Senate version as-is, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, ... medications in select Florida and Texas doctors' offices and clinics. This breakthrough testing ... of genetic testing recognizes the role genes play in determining an individual's tolerance ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... announced the launch of Care Management Alerts and Dashboards, an innovative new service ... Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: